US OptionsDetailed Quotes
SGMO241220C5000
- 0.05
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume2.37K Open Interest5.00Strike Price0.00Turnover0.00%IV104.45%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma49.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Sangamo Therapeutics Stock Discussion
Should be interesting to see what we get in up front. It's been given Accelerated Approval by FDA so BLA will be filed next year sometime once we get final patient data. I'm guessing 100 to 200 million up front.
The STAC-BBB capsid technology addresses one of gene therapy's most challenging obstacles - crossing the blood-brain barrier efficiently. Traditional AAV vectors struggle with CNS penetration, often requiring invasive direct administration. An effective IV-delivered solution could revolutionize neurological gene therapy by enabling broader distribution and simplified administration.
The non-human primate data showing potent BBB ...
The $20 million upfront payment and potential $1.3 billion in milestone payments represent a significant cash infusion for Sangamo, whose current market cap is around $486 million. The deal structure, with tiered mid-to-high single-digit royalties, follows industry standards for early-stage biotech licensing agreements. The immediate cash boost strengthens Sangamo's balance sheet and extends their operational runway.
The agreement's va...
Sangamo Therapeutics (SGMO) shares were up over 15% amid a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said. The consideration for the deal includes a $20 million upfront license payment.
Late on posting this but here it is. I'm not trading again today, not focused on it anyways, maybe some quick in and outs.
Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Positive
Secured $20 million upfront license fee from Astellas
Potential to earn up to $1.3 billion in additional fees and milestone payments
Will receive tiered mid-to-high single-digit royalties on potential net sales
N...
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Currenc Group (CURR.US)$ Despac Sk...
No comment yet